Biomarker ID | 981 |
PMID | 22956952 |
Year | 2012 |
Biomarker | ACOT11-001; AOX1-001; C19orf46-002; C8orf84-001; COCH-202; CTA-55I10.1;001; DMD-024; FGF10-002 ;FGFR2-008; FGFR2-016; GABRE-006; GNAL-001; GNAO1-002; HEATR8-006; ISL1-002; NR2F2-202; PCP4-004; PDE5A-005; PDZRN4-202; RSRC2-017; TGM4-001; TSPAN2-001; ABCC4-004; ALK-001; ATP1A1-002; NAMPT-006; NAMPT-007; RP11-627G23.1-004; |
Biomarker Basis | Expression Based |
Biomolecule | genes or ncRNA |
Source | Tissue |
Subjects | Humans |
Regulation | NA |
Odds Ratio/Hazard Ratio/Relative Risk | KNN model based on transcripts: OR: 13 (95% CI: 2.5–99) ; KNN model based on transcripts: OR: 3.8,[1.0–14.3] |
Effect on Pathways | NA |
Experiment | Biochemical Recurrence |
Type of Biomarker | Prognostic |
Cohort | The human exon array files for 131 primary prostate cancer tumors, 29 normal adjacent and 19 metastatic tissue specimens were downloaded from GEO at GSE21034. |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p<0.005 |
Method Used | Microarray |
Clinical | No |
Remarks | Improved performace over Nomogram |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | ACOT11-001, AOX1-001, C19orf46-002, C8orf84-001, COCH-202, CTA-55I10.1, 001, DMD-024, FGF10-002, FGFR2-008, FGFR2-016, GABRE-006, GNAL-001, GNAO1-002, HEATR8-006, ISL1-002, NR2F2-202, PCP4-004, PDE5A-005, PDZRN4-202, RSRC2-017, TGM4-001, TSPAN2-001, ABCC4-004, ALK-001, ATP1A1-002, NAMPT-006, NAMPT-007, RP11-627G23.1-004 |